tetano
Editor, Senior Moderator
Viruses
. 2022 Apr 21;14(5):854.
doi: 10.3390/v14050854.
The E484K Substitution in a SARS-CoV-2 Spike Protein Subunit Vaccine Resulted in Limited Cross-Reactive Neutralizing Antibody Responses in Mice
Longbo Hu[SUP] 1 [/SUP], Yuhua Xu[SUP] 2 [/SUP], Liping Wu[SUP] 1 [/SUP], Jin Feng[SUP] 1 2 3 [/SUP], Lu Zhang[SUP] 4 [/SUP], Yongjie Tang[SUP] 1 [/SUP], Xiang Zhao[SUP] 1 [/SUP], Runming Mai[SUP] 2 [/SUP], Liyun Chen[SUP] 2 [/SUP], Lingling Mei[SUP] 1 [/SUP], Yuanzhen Tan[SUP] 2 [/SUP], Yingying Du[SUP] 2 [/SUP], Yanping Zhen[SUP] 2 [/SUP], Wenhan Su[SUP] 2 [/SUP], Tao Peng[SUP] 1 2 [/SUP]
Affiliations
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), especially emerging variants, poses an increased threat to global public health. The significant reduction in neutralization activity against the variants such as B.1.351 in the serum of convalescent patients and vaccinated people calls for the design of new potent vaccines targeting the emerging variant. However, since most vaccines approved and in clinical trials are based on the sequence of the original SARS-CoV-2 strain, the immunogenicity and protective efficacy of vaccines based on the B.1.351 variant remain largely unknown. In this study, we evaluated the immunogenicity, induced neutralization activity, and protective efficacy of wild-type spike protein nanoparticle (S-2P) and mutant spike protein nanoparticle (S-4M-2P) carrying characteristic mutations of B.1.351 variant in mice. Although there was no significant difference in the induction of spike-specific IgG responses in S-2P- and S-4M-2P-immunized mice, neutralizing antibodies elicited by S-4M-2P exhibited noteworthy, narrower breadth of reactivity with SARS-CoV-2 variants compared with neutralizing antibodies elicited by S-2P. Furthermore, the decrease of induced neutralizing antibody breadth at least partly resulted from the amino acid substitution at position 484. Moreover, S-4M-2P vaccination conferred insufficient protection against live SARS-CoV-2 virus infection, while S-2P vaccination gave definite protection against SARS-CoV-2 challenge in mice. Together, our study provides direct evidence that the E484K substitution in a SARS-CoV-2 subunit protein vaccine limited the cross-reactive neutralizing antibody breadth in mice and, more importantly, draws attention to the unfavorable impact of this mutation in spike protein of SARS-CoV-2 variants on the induction of potent neutralizing antibody responses.
Keywords: B.1.351; E484K; SARS-CoV-2; neutralizing antibody; subunit vaccine.
. 2022 Apr 21;14(5):854.
doi: 10.3390/v14050854.
The E484K Substitution in a SARS-CoV-2 Spike Protein Subunit Vaccine Resulted in Limited Cross-Reactive Neutralizing Antibody Responses in Mice
Longbo Hu[SUP] 1 [/SUP], Yuhua Xu[SUP] 2 [/SUP], Liping Wu[SUP] 1 [/SUP], Jin Feng[SUP] 1 2 3 [/SUP], Lu Zhang[SUP] 4 [/SUP], Yongjie Tang[SUP] 1 [/SUP], Xiang Zhao[SUP] 1 [/SUP], Runming Mai[SUP] 2 [/SUP], Liyun Chen[SUP] 2 [/SUP], Lingling Mei[SUP] 1 [/SUP], Yuanzhen Tan[SUP] 2 [/SUP], Yingying Du[SUP] 2 [/SUP], Yanping Zhen[SUP] 2 [/SUP], Wenhan Su[SUP] 2 [/SUP], Tao Peng[SUP] 1 2 [/SUP]
Affiliations
- PMID: 35632595
- DOI: 10.3390/v14050854
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), especially emerging variants, poses an increased threat to global public health. The significant reduction in neutralization activity against the variants such as B.1.351 in the serum of convalescent patients and vaccinated people calls for the design of new potent vaccines targeting the emerging variant. However, since most vaccines approved and in clinical trials are based on the sequence of the original SARS-CoV-2 strain, the immunogenicity and protective efficacy of vaccines based on the B.1.351 variant remain largely unknown. In this study, we evaluated the immunogenicity, induced neutralization activity, and protective efficacy of wild-type spike protein nanoparticle (S-2P) and mutant spike protein nanoparticle (S-4M-2P) carrying characteristic mutations of B.1.351 variant in mice. Although there was no significant difference in the induction of spike-specific IgG responses in S-2P- and S-4M-2P-immunized mice, neutralizing antibodies elicited by S-4M-2P exhibited noteworthy, narrower breadth of reactivity with SARS-CoV-2 variants compared with neutralizing antibodies elicited by S-2P. Furthermore, the decrease of induced neutralizing antibody breadth at least partly resulted from the amino acid substitution at position 484. Moreover, S-4M-2P vaccination conferred insufficient protection against live SARS-CoV-2 virus infection, while S-2P vaccination gave definite protection against SARS-CoV-2 challenge in mice. Together, our study provides direct evidence that the E484K substitution in a SARS-CoV-2 subunit protein vaccine limited the cross-reactive neutralizing antibody breadth in mice and, more importantly, draws attention to the unfavorable impact of this mutation in spike protein of SARS-CoV-2 variants on the induction of potent neutralizing antibody responses.
Keywords: B.1.351; E484K; SARS-CoV-2; neutralizing antibody; subunit vaccine.